Overactive Bladder Features

CME Articles

OAB: Current and Emerging Therapies for Optimal Individualized Treatment

Keeping abreast of the most current treatments for idiopathic OAB can lead to improved outcomes and quality of life.

Expert Q&A Botox for Urinary Incontinence: Interview with David Sussman, DO

Botox for Urinary Incontinence: Interview with David Sussman, DO

David O. Sussman, DO, has been ready to educate urology colleagues on the appropriate use of Botox.

Latest Overactive Bladder News

OAB, SUI Worse After Vaginal Birth

OAB, SUI Worse After Vaginal Birth

Regardless of delivery type, obesity ups the risk of more severe urinary symptoms, study shows.

Overactive Bladder Found to Raise Nocturia Risk

Overactive Bladder Found to Raise Nocturia Risk

In a study, severe nocturia predicted increased mortality risk.

Combined High-Dosage Drugs Shown to Ease Resistant OAB

Elderly patients with OAB may benefit from combined high-dosage antimuscarinics.

Repeat BTXA Injections Okay for Non-Neurogenic OAB

Repeat injections of onabotulinumtoxinA (BTXA) appear to benefit patients with non-neurogenic overactive bladder.

Stubborn Overactive Bladder Responds to Sacral Neuromodulation

Improvements in efficacy and quality of life last at least six months, study finds.

Nocturia Bidirectionally Linked with Depression

Nocturia Bidirectionally Linked with Depression

Depression risk greater for men with nocturia than for women with nocturia.

Desmopressin Effective for Nocturia in Women

Desmopressin Effective for Nocturia in Women

Two studies show significant reduction in number of nocturnal voids for women.

Percutaneous Tibial Nerve Stimulation Has Lasting Benefit

Percutaneous Tibial Nerve Stimulation Has Lasting Benefit

In most responders, overactive bladder symptom improvement sustained to three years.

FDA: Phony Botox Purveyors Targeting U.S. Practices

FDA: Phony Botox Purveyors Targeting U.S. Practices

Products advertised through fax; not FDA approved.

FDA Approves 1st OTC Drug for Women With Overactive Bladder

FDA Approves 1st OTC Drug for Women With Overactive Bladder

Oxytrol is intended for use by those 18 and older.

Increasing Solifenacin Dose Can Improve Outcomes in Severe OAB

Increasing the daily dose from 5 to 10 mg resulted in reductions in mean total urgency score and mean micturition frequency.

FDA Approves Botox for Overactive Bladder

The FDA has approved onabotulinumtoxinA (Botox) as a treatment for overactive bladder (OAB) in adults who are inadequately managed with anticholinergic medications.

Overactive Bladder Risk Higher in Diabetics

Patients with type 2 diabetes are twice as likely as nondiabetics to suffer from the condition.

New Overactive Bladder Drug Approved

Mirabegron is the first oral OAB drug with a distinct mechanism of action to be approved in three decades.

Fesoterodine Relieves Nocturnal Urgency in OAB Patients

Flexible-dose fesoterodine is superior to placebo in decreasing the number of nocturnal urgency episodes and nocturnal micturitions in patients with overactive bladder (OAB), researchers reported at the American Urological Association 2012 annual meeting.